Primary aldosteronism and potassium channel mutations

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 3, 2013, Pages 170-179

  Stowasser, Michael ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Etiology; Genetics; Potassium channels; Primary aldosteronism

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; CORTICOTROPIN; G PROTEIN COUPLED RECEPTOR; HYDROCORTISONE; INWARDLY RECTIFYING POTASSIUM CHANNEL; KCNJ5 PROTEIN; POTASSIUM CHANNEL; PROTEIN; SODIUM CHANNEL; STEROID 17ALPHA MONOOXYGENASE; UNCLASSIFIED DRUG;

ADRENAL CELL; ADRENAL CORTEX CELL; ADRENAL HYPERPLASIA; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; CALCIUM CELL LEVEL; CELL MEMBRANE DEPOLARIZATION; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; ENZYME ACTIVITY; GENE DELETION; GENE MUTATION; HUMAN; HYBRID GENE; HYPERTENSION; HYPOKALEMIA; MEMBRANE DEPOLARIZATION; NONHUMAN; PATHOGENESIS; PRIMARY HYPERALDOSTERONISM; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; ZONA FASCICULATA; ZONA GLOMERULOSA;

AMINO ACID SUBSTITUTION; ANIMALS; ETHER-A-GO-GO POTASSIUM CHANNELS; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HUMANS; HYPERALDOSTERONISM; MUTATION; POTASSIUM CHANNELS; SEVERITY OF ILLNESS INDEX;

EID: 84879206567     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e32835ef2fd     Document Type: Review

References (40)

1. Conn JW. The evolution of primary aldosteronism: 1954-1967. Harvey Lect 1966; 62:257-291.
2. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab 2009; 94:3623-3630.
3. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966; 95:1109-1119.
4. Stowasser M, Bachmann AW, Huggard PR, et al. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab 2000; 85:3313- 3318.
5. Lifton RP, Dluhy RG, Powers M, et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 1992; 2:66-74.
6. Jonsson JR, Klemm SA, Tunny TJ, et al. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995; 207:565-571.
7. Stowasser M, Pimenta E, Gordon RD. Familial or genetic primary aldosteronism and Gordon syndrome. Endocrinol Metab Clin North Am 2011; 40:343- 368.
8. Newton-Cheh C, Guo CY, Gona P, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 2007; 49:846-856. (Pubitemid 351664212)
9. Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004; 84:489-539. (Pubitemid 38365491)
10. Lotshaw DP. Role of membrane depolarization and T-type Ca2+ channels in angiotensin II and K+ stimulated aldosterone secretion. Mol Cell Endocrinol 2001; 175:157-171. (Pubitemid 32372552)
11. Czirjak G, Enyedi P. TASK-3 dominates the background potassium conductance in rat adrenal glomerulosa cells. Mol Endocrinol 2002; 16:621-629. (Pubitemid 34214580)
12. Czirjak G, Enyedi P. Formation of functional heterodimers between the TASK-1 and TASK-3 two-pore domain potassium channel subunits. J Biol Chem 2002; 277:5426-5432. (Pubitemid 34968590)
13. Conti M. Targeting K+ channels for cancer therapy. J Exp Ther Oncol 2004; 4:161-166.
14. Sausbier M, Arntz C, Bucurenciu I, et al. Elevated blood pressure linked to primary hyperaldosteronism and impaired vasodilation in BK channel-deficient mice. Circulation 2005; 112:60-68. (Pubitemid 40962570)
15. Davies LA, Hu C, Guagliardo NA, et al. TASK channel deletion in mice causes primary hyperaldosteronism. Proc Natl Acad Sci U S A 2008; 105:2203- 2208. (Pubitemid 351439489)
16. Guagliardo NA, Yao J, Hu C, et al. TASK-3 channel deletion in mice recapitulates low-renin essential hypertension. Hypertension 2012; 59:999-1005.
17. Heitzmann D, Derand R, Jungbauer S, et al. Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. Embo J 2008; 27:179-187.
18. Nogueira EF, Gerry D, Mantero F, et al. The role of TASK1 in aldosterone production and its expression in normal adrenal and aldosterone-producing adenomas. Clin Endocrinol 2010; 73:22-29.
19. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80:795- 803.
20. Itoh T, Tanaka T, Nagai R, et al. Genomic organization and mutational analysis of HERG, a gene responsible for familial long QT syndrome. Hum Genet 1998; 102:435-439. (Pubitemid 28203985)
21. Sarzani R, Pietrucci F, Corinaldesi C, et al. The functional HERG variant 897T is associated with Conn's adenoma. J Hypertens 2006; 24:479-487. (Pubitemid 43261912)
22. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosteroneproducing adenomas and hereditary hypertension. Science 2011; 331:768- 772.
23. Mulatero P, Tauber P, Zennaro MC, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012; 59:235-240.
24. Boulkroun S, Beuschlein F, Rossi GP, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012; 59:592-598.
25. Azizan EA, Murthy M, Stowasser M, et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012; 59:587-591.
26. Azizan EA, Lam BY, Newhouse SJ, et al. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. J Clin Endocrinol Metab 2012; 97:E819-829.
27. Akerstrom T, Crona J, Delgado VA, et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS ONE 2012; 7:e41926.
28. Monticone S, Hattangady NG, Nishimoto K, et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab 2012; 97:E1567-1572.
29. Taguchi R, Yamada M, Nakajima Y, et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab 2012; 97:1311-1319.
30. Xekouki P, Hatch MM, Lin L, et al. KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: an infrequent genetic cause of Conn's syndrome. Endocr-Relat Cancer 2012; 19:255- 260.
31. Geller DS, Zhang J, Wisgerhof MV, et al. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 2008; 93:3117-3123.
32. Scholl UI, Nelson-Williams C, Yue P, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A 2012; 109:2533-2538.
33. Charmandari E, Sertedaki A, Kino T, et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab 2012; 97:E1532- 1539.
34. Oki K, Plonczynski MW, Luis LM, et al. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology 2012; 153:1774-1782.
35. Mulatero P, Stowasser M, Loh KC, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89:1045-1050. (Pubitemid 38368386)
36. Omura M, Saito J, Yamaguchi K, et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27:193-202. (Pubitemid 38489081)
37. Omura M, Sasano H, Saito J, et al. Clinical characteristics of aldosteroneproducing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism. Hypertens Res 2006; 29:883- 889. (Pubitemid 46062119)
38. Gordon RD, Hamlet SM, Tunny TJ, et al. Aldosterone-producing adenomas responsive to angiotensin pose problems in diagnosis. Clin Exp Pharmacol Physiol 1987; 14:175-179. (Pubitemid 18002635)
39. Tunny TJ, Gordon RD, Klemm SA, et al. Histological and biochemical distinctiveness of atypical aldosterone-producing adenomas responsive to upright posture and angiotensin. Clin Endocrinol (Oxf) 1991; 34:363-369.
40. Stowasser M, KlemmSA, Tunny TJ, et al. Response to unilateral adrenalectomy for aldosterone-producing adenoma: effect of potassiumlevels and angiotensin responsiveness. Clin Exp Pharmacol Physiol 1994; 21:319-322. (Pubitemid 24201226)